Climb Bio, Inc. — Director's Dealing 2021

Aug 10, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Eliem Therapeutics, Inc. (ELYM)
CIK: 0001768446
Period of Report: 2021-08-09

Reporting Person: AI ETI LLC (10% Owner)
Reporting Person: Access Industries Holdings LLC (Affiliate of 10% Owner)
Reporting Person: ACCESS INDUSTRIES MANAGEMENT, LLC (Affiliate of 10% Owner)
Reporting Person: Blavatnik Len (Affiliate of 10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Redeemable Convertible Preferred Stock	$		Common Stock (3568375)		Direct
Series B Redeemable Convertible Preferred Stock	$		Common Stock (641025)		Direct

Footnotes

F1: Each outstanding share of Series A Redeemable Convertible Preferred Stock will automatically convert into one share of common stock of Eliem Therapeutics, Inc. (the "Issuer") immediately prior to the completion of the Issuer's initial public offering and has no expiration date.

F2: The securities reported are held directly by AI ETI LLC and may be deemed to be beneficially owned by Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because AIH indirectly controls all of the outstanding voting interests in AI ETI LLC, AIM controls AIH and Mr. Blavatnik controls AIM and holds a majority of the outstanding voting interests in AIH. AIH, AIM and Mr. Blavatnik each disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form.

F3: Each outstanding share of Series B Redeemable Convertible Preferred Stock will automatically convert into one share of common stock of the Issuer immediately prior to the completion of the Issuer's initial public offering and has no expiration date.